← Back to Search

18F-DA PET Scan for Neuroblastoma

Q: How many individuals have been included in this experiment thus far?

<p>Indeed, the data hosted on clinicaltrials.gov affirms that this research endeavour is presently recruiting for participants. This trial was initially published on March 14th 2019 and last amended on February 15th 2022; 20 people are needed at one site to join in.</p>

Q: Are there any remaining vacancies for participants in this experiment?

<p>Data from clinicaltrials.gov indicates that, as of this time, enrollment for the trial is open. Initially posted on March 14th 2019, it was last updated on February 15th 2022.</p>

Phase < 1

Recruiting

Led By Barry Shulkin, MD

Research Sponsored by St. Jude Children's Research Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to half year following injection of the radiotracer 18f-da.

Awards & highlights

Study Summary

This trial will use PET scans combined with a radioactive tracer (18F-DA) to examine neuroblastoma tumors. The goal is to see if this tracer is safe and more effective than the current standard (123I-mIBG).

Who is the study for?

This trial is for children over 1 year old with known or suspected neuroblastoma or pheochromocytoma, under a St. Jude physician's care. Participants must not be pregnant, breastfeeding, and should avoid pregnancy within one month after the scan. Those on certain medications may need to stop them before joining.Check my eligibility

What is being tested?

The study tests if a PET scan using the tracer 18F-DA is safe and more effective than the current standard (123I-mIBG) in detecting small areas of neuroblastoma and pheochromocytoma tumors in about 20 patients at St. Jude.See study design

What are the potential side effects?

While specific side effects are not listed for this imaging study, potential risks generally include exposure to radiation which could lead to long-term health issues like cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to half year following injection of the radiotracer 18f-da.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to half year following injection of the radiotracer 18f-da.

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to half year following injection of the radiotracer 18f-da. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Adverse event rate

Secondary outcome measures

The frequency of localization of 18F-DA in different organs.

max SUV from 18F-DA and 123I-mIBG PET

Other outcome measures

Mean and standard deviation of the difference of Curie scoring of 18F-DA and 123I-mIBG imaging

Trial Design

1Treatment groups

Experimental Treatment

Group I: Injection of 18F-DAExperimental Treatment1 Intervention

18F-DA will be injected into a vein in the arm or leg, or via central venous access line.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

St. Jude Children's Research HospitalLead Sponsor

428 Previous Clinical Trials

5,306,593 Total Patients Enrolled

23 Trials studying Neuroblastoma

7,004 Patients Enrolled for Neuroblastoma

Barry Shulkin, MDPrincipal InvestigatorSt. Jude Children's Research Hospital

Media Library

18F-DA Clinical Trial Eligibility Overview. Trial Name: NCT03541720 — Phase < 1

Neuroblastoma Research Study Groups: Injection of 18F-DA

Neuroblastoma Clinical Trial 2023: 18F-DA Highlights & Side Effects. Trial Name: NCT03541720 — Phase < 1

18F-DA 2023 Treatment Timeline for Medical Study. Trial Name: NCT03541720 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals have been included in this experiment thus far?

"Indeed, the data hosted on clinicaltrials.gov affirms that this research endeavour is presently recruiting for participants. This trial was initially published on March 14th 2019 and last amended on February 15th 2022; 20 people are needed at one site to join in."

Answered by AI

Are there any remaining vacancies for participants in this experiment?

"Data from clinicaltrials.gov indicates that, as of this time, enrollment for the trial is open. Initially posted on March 14th 2019, it was last updated on February 15th 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma

2019. "18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03541720.

All > Pheochromocytoma > Neuroblastoma